The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2025 | The growing role of quadruplet-based regimens in newly diagnosed multiple myeloma
Hans Lee, MD, Sarah Cannon Research Institute, Nashville, TN, briefly discusses advances in the treatment of newly diagnosed multiple myeloma, highlighting the incorporation of quadruplet-based induction regimens as the standard of care. This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
There have been a number of advances in the treatment of newly diagnosed multiple myeloma, namely the incorporation of quadruplet-based induction regimens for patients with newly diagnosed myeloma, whether they’re transplant eligible or ineligible. So I think it’s firmly established that CD38 proteasome inhibitor IMiD combinations, lenalidomide combinations, are the standard care for newly diagnosed multiple myeloma...
There have been a number of advances in the treatment of newly diagnosed multiple myeloma, namely the incorporation of quadruplet-based induction regimens for patients with newly diagnosed myeloma, whether they’re transplant eligible or ineligible. So I think it’s firmly established that CD38 proteasome inhibitor IMiD combinations, lenalidomide combinations, are the standard care for newly diagnosed multiple myeloma. In a patient who is quad eligible, then I definitely would consider administering the quadruple-based induction therapy, plus or minus transplant. I think the role of transplant is continually involved, especially based on the recently published MIDAS trial, which demonstrates in patients with standard risk multiple myeloma, potentially there could be a role to defer upfront transplant in this context. In patients who may not be quad eligible, then doing a triplet-based regimen would be the optimal induction regimen, either daratumumab, lenalidomide, dexamethasone, or potentially VRd, bortezomib, lenalidomide, dexamethasone for patients who may not be quad eligible.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
